Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 1, 2000, Pages 186-189

  Spangler, Sheila K ^a   Bajaksouzian, Saralee ^b   Jacobs, Michael R ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; CLARITHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; SPARFLOXACIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIOSTASIS; BACTERIUM ISOLATION; CELL VIABILITY; DRUG DETERMINATION; DRUG EFFECT; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0033989550     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.1.186-189.2000     Document Type: Article

References (18)

1. Child, J., J. M. Andrews, and R. Wise. 1995. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrob. Agents Chemother. 39:513-515.
2. Cook, P. J., J. M. Andrews, R. Wise, D. Honeybourne, and H. Moudgil. 1995. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J. Antimicrob. Chemother. 35:317-326.
3. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md.
4. Doern, G. V., A. Brueggeman, H. P. Holley, Jr., and A. M. Rauch. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40:1208-1213.
5. Doern, G. V., A. B. Brueggeman, G. Pierce, H. P. Holley, Jr., and A. Rauch. 1997. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob. Agents Chemother. 41:292-297.
6. Efthymiopoulos, C., S. L. Bramer, and A. Maroli. 1997. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin. Pharmacokinet. 33(Suppl. 1):1-8.
7. Friedland, I. R., and G. H. McCracken, Jr. 1994. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J. Med. 331:377-382.
8. Fuursted, K., J. D. Knudsen, M. B. Petersen, R. K. Poulsen, and D. Rehm. 1997. Comparative study of bactericidal activities, postantibiotic effects, and effects on bacterial virulence of penicillin G and six macrolides against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:781-784.
9. Imada, T., S. Miyazaki, M. Nishida, K. Yamaguchi, and S. Goto. 1992. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob. Agents Chemother. 36:573-579.
10. Jacobs, M. R., and P. C. Appelbaum. 1995. Antibiotic-resistant pneumococci. Rev. Med. Microbiol. 6:77-93.
11. Licata, L., C. E. Smith, R. M. Goldschmidt, J. F. Barrett, and M. Frosco. 1997. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxadn on Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:950-955.
12. Marco, F., R. N. Jones, D. J. Hoban, A. C. Pignatari, N. Yamane, and R. Frei. 1994. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. J. Antimicrob. Chemother. 33:647-654.
13. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. NCCLS publication no. M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Odenholt-Tornqvist, I. 1993. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J. Antimicrob. Chemother. 31:881-892.
15. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1995. Activity of CP 99,219 compared to DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J. Antimiciob. Chemother. 35:230-232.
16. Spangler, S. K., G. Lin, M. R. Jacobs, and P. C. Appelbaum. 1997. Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 41:2173-2176.
17. Spangler, S. K., G. Lin, M. R. Jacobs, and P. C. Appelbaum. 1998. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, etythromycin, azithromycin, and clarithromycin against 20 pneumococci. Antimicrob. Agents Chemother. 42:1253-1255.
18. Wise, R., J. M. Andrews, and N. Brenwald. 1993. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J. Antimicrob. Chemother. 31:497-504.